Buspirone: future directions
by
Apter JT, Allen LA
Princeton Biomedical Research, PA, New Jersey, USA.
J Clin Psychopharmacol 1999 Feb; 19(1):86-93

ABSTRACT

The Food and Drug Administration approved the use of buspirone for generalized anxiety disorder (GAD) in 1986. Since then, numerous studies have examined the efficacy and safety of buspirone for patients with not only generalized feelings of anxiety, but also panic disorder, major depressive disorder, obsessive-compulsive disorder, body dysmorphic disorder, social phobia, posttraumatic stress disorder, selective serotonin reuptake inhibitor-induced adverse events, dementia, behavioral disturbances, attention deficit-hyperactivity disorder, and tobacco dependency. Although relatively few placebo-controlled trials have been conducted on patients with problems other than GAD, an ever-growing body of research suggests future directions for the use of buspirone. This article reviews the body of research relating to new uses for buspirone.

OCD
PTSD
ADHD
SSRIs
5-HT1a
Anxiety
Gepirone
Serotonin
Ipsapirone
Eltoprazine
Aggression
Future anxiolytics
Buspirone plus pindolol
Buspirone: mechanisms
Buspirone v clorazepate
Buspirone plus venlafaxine
Buspirone: pharmocokinetics
Buspirone and 5-HT1a receptors
Buspirone (Buspar): prescribing information (PDF)
Buspirone (Buspar) extended- v immediate-release

Refs
HOME
HedWeb
Future Opioids
BLTC Research
Paradise-Engineering
The Hedonistic Imperative
When Is It Best To Take Crack Cocaine?

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family